Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026
Lilly presented first Phase 1 clinical data at ESMO 2026 showing its FRα-targeting ADC sofetabart mipitecan (Sofe-M) plus bevacizumab achieved a 79.3% confirmed objective response rate and 100% disease control rate in platinum-sensitive ovarian cancer. Activity was consistent regardless of FRα expression level or prior PARP inhibitor exposure, a heavily pretreated population where platinum re-challenge typically delivers only ~42% response rates. Median duration of response and PFS were not reached, and no new safety signals were observed.
Key figures
- Drug Name
- sofetabart mipitecan (Sofe-M; LY4170156)
- Phase Of Trial
- Phase 1
- Partial responses
- 58.6%
- Prior bevacizumab
- 70%
- Complete responses
- 20.7%
- Grade3 neutropenia
- 42%
- Disease control rate
- 100%
- Prior parp inhibitor
- 67%
- Psoc cohort patients
- 33
- Discontinuation due to ae
- 6%
- Median followup dor months
- 6.2
- Median followup pfs months
- 10.2
- Measurable disease patients
- 29
- Confirmed objective response rate
- 79.3%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.